Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1087 of 6351
-
Gene test could match prostate cancer patients to better chemo
Disease control OngoingProstate cancer (PrCa) is one of the commonest cancer in men in the Western world. In the United Kingdom (UK), there were over 52,000 new cases diagnosed in 2016-2018 and a lifetime risk of 1 in 8. Research studies have identified several genetic changes that are thought to incre…
Phase 2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New drug cocktail shows promise against tough pancreatic cancer
Disease control CompletedThe purpose of this study is to determine if the combination of paclitaxel protein bound, gemcitabine, cisplatin, paricalcitol are effective in individuals with resectable and unresectable pancreatic cancer.
Phase 2 • Sponsor: HonorHealth Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Can online neck exercises beat standard rehab after spine surgery?
Disease control CompletedBackground: Patients suffering residual disability after anterior decompression and fusion (ACDF) surgery for cervical disc disease may be prescribed physical activity (PPA) or neck-specific exercises (NSE). Currently, we lack data for the success of either approach. There is als…
Sponsor: Linkoeping University • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New hope for kids with rare cancers: drug targets tumor growth
Disease control OngoingThis phase II trial studies how well cabozantinib-s-malate works in treating younger patients with sarcomas, Wilms tumor, or other rare tumors that have come back, do not respond to therapy, or are newly diagnosed. Cabozantinib-s-malate may stop the growth of tumor cells by block…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Immunotherapy combo shows promise for Hard-to-Treat ovarian cancer
Disease control CompletedThis phase II trial studies how well durvalumab and tremelimumab work in treating participants with ovarian, primary peritoneal, or fallopian tube cancer that has come back or does not respond to treatment. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelim…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can targeted radiation retrain recurrent brain tumors?
Disease control CompletedFractionated radiosurgery will be delivered to atypical meningioma lesions in salvage setting for patients who present post-surgical residual lesion or develop recurrence.
Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Keyhole surgery in the womb: a new hope for spina bifida?
Disease control CompletedThe purpose of this study is to determine the feasibility of prenatal minimally-invasive fetoscopic closure with i) uterine exteriorization for a minimally-invasive repair under amniotic carbon dioxide insufflation ii) two trocars for the dissection and the cover with one patch o…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 26, 2026 14:43 UTC
-
Could a new drug save pregnancies in women with a rare blood disorder?
Disease control Recruiting nowThis treatment trial evaluates the addition of an anti-tumor necrosis factor-alpha drug, certolizumab, to usual treatment (a heparin agent and low-dose aspirin) in pregnant women with antiphospholipid syndrome (APS) and repeatedly positive tests for lupus anticoagulant (LAC) to d…
Phase 2 • Sponsor: David Ware Branch • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Experimental treatment aims to boost mitochondrial DNA in rare disease
Disease control OngoingPatients with confirmed mitochondrial DNA depletion syndrome 2 (thymidine kinase 2 \[TK2\] deficiency) have reduced levels of nucleotides (deoxythymidine monophosphate and deoxycytidine monophosphate) for mitochondrial DNA synthesis. This results in mitochondrial DNA depletion sy…
Phase 1/2 • Sponsor: Columbia University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New antibody therapy shows promise for Hard-to-Treat multiple myeloma
Disease control OngoingThe purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for Teclistamab and to characterize the safety and tolerability of Teclistamab at the RP2Ds.
Phase 1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Engineered immune cells take aim at multiple cancers in early trial
Disease control OngoingThis study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung, esophageal, gastric, synovial sarcoma, or myxoid/round…
Phase 1 • Sponsor: USWM CT, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
A simple blood draw could spot tumor relapse before scans do
Diagnosis CompletedThe purpose of this study is to evaluate the effect of different surgical resections (R0, R1, R2) on circulating NET transcripts (PCR score or NETest). A drop in circulating NET levels will be correlated with surgical excision. Secondly, variation of circulating NET transcripts w…
Sponsor: Wren Laboratories LLC • Aim: Diagnosis
Last updated Aug 23, 2026 00:00 UTC
-
Triple threat: new combo aims to stop lung cancer in its tracks
Disease control OngoingThis is a single-arm, single-stage Phase II study designed to evaluate the 1-year PFS rate in subjects with locally-advanced NSCLC (stage II/III) and treated with Stereotactic Body Radiation Therapy (SBRT) followed by concurrent mediastinal chemoradiation with or without consolid…
Phase 2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Keyhole surgery in the womb could fix spina bifida with fewer risks
Disease control OngoingThe purpose of this investigation is to evaluate maternal and fetal outcomes following fetoscopic repair of fetal spina bifida at the Johns Hopkins Hospital. The hypothesis of this study is that fetoscopic spina bifida repair is feasible and has the same effectiveness as open re…
Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New combo aims to extend life in stomach cancer
Disease control CompletedThis clinical trial will evaluate whether it is beneficial in terms of prolongation of survival to combine FOLFIRI (standard treatment) with ramucirumab compared to the standard treatment of ramucirumab plus paclitaxel in patients with advanced gastric cancer after failure of one…
Phase 2/3 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Heart valve showdown: TAVI vs surgery in Mid-Risk patients
Disease control OngoingRandomized controlled, multi-center trial randomizing patients with symptomatic severe aortic stenosis at low to intermediate operative risk of mortality in a 1:1 fashion to transcatheter aortic valve implantation (TAVI) or surgical aortic valve replacement (SAVR) to test, whethe…
Sponsor: Universitätsklinikum Hamburg-Eppendorf • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Immunotherapy cocktail targets tough cancers
Disease control OngoingThis research study is studying a combination of drugs with radiation therapy as a possible treatment for Microsatellite Stable Colorectal Cancer, Pancreatic Cancer, or MSI High Colorectal Cancer. The interventions involved in this study are: * Nivolumab * Ipilimumab * Radiatio…
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Immunotherapy drug may delay return of aggressive head and neck cancers
Disease control CompletedA placebo-controlled, randomized study using adjuvant pembrolizumab treatment for one year in order to potentially improve progression free survival in a squamous cell carcinoma of the head and neck cohort at high-risk for recurrence.
Phase 2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Double-Drug attack: new combo targets tough lung cancer
Disease control OngoingThis research study is studying a combination of two drugs as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation. The interventions involved in this study are: * Osimertinib (Tagrisso) * Gefitinib (Iressa)
Phase 1/2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Engineered immune cells take on liver cancer in early trial
Disease control CompletedThis first time in human study is intended for men and women between 18 and 75 years of age who have advanced liver cancer which has grown or returned after being treated or another AFP expressing tumor. Those who did not tolerate or refused other therapies may also participate. …
Phase 1 • Sponsor: Adaptimmune • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC